Debate over compounding bill centers on supplier verification, patient safety and access
Loading...
Summary
HB 2,613 would require tighter quality-assurance measures for compounded drugs; drugmakers and patient‑safety groups urged safeguards targeting high‑volume, mass‑marketed compounded GLP‑1 products, while pharmacists, hospitals and community clinics warned the bill as written would overreach, raise costs, delay care and risk limiting essential patient‑specific compounding.
Lawmakers, industry and healthcare providers offered sharply contrasting views Friday during a public hearing on House Bill 2,613, which would tighten quality‑assurance and supply‑chain verification requirements for compounded drugs.
Emily Poole, committee staff, told the House Health Care and Wellness Committee the bill would prohibit sale, transfer or distribution of a compounded drug unless the compounder uses bulk drug substances that meet national standards or appear on an FDA list, maintains certificates of analysis, performs quality control testing, and can show the manufacturer of the bulk substance is FDA‑registered and inspected within the last two years. The bill also would require two years of record retention and authorizes the pharmacy commission to conduct compliance inspections.
Representative Milin Tai, the bill’s prime sponsor, said she introduced HB 2,613 to reinforce safeguards after seeing widely marketed and poorly documented products. She invited technical fixes and said she would work with stakeholders on scope.
Pharmaceutical manufacturers and public‑health groups urged a targeted approach. Michael Transsew and Gabrielle Cosell, speaking for Novo Nordisk, said the rapid growth of compounded versions of newly approved drugs—particularly injectable GLP‑1 weight‑loss products—has produced a novel patient‑safety problem. Cosell described testing examples submitted with written testimony and cited one compounded semaglutide sample with 86.2% impurities. Novo Nordisk said it wants amendments that narrow the bill to high‑risk mass‑market compounding and exempt hospitals, nursing homes and veterinary compounding.
Pharmacists, hospitals and physician groups testified in opposition or with caution. Jenny Arnold (Washington State Pharmacy Association) and Dr. Dawn Ipsen (compounding pharmacist) said Washington already enforces rigorous USP‑aligned compounding rules, that mandatory supplier inspection and exhaustive in‑house testing could duplicate federal authority, and that the bill as drafted could limit access to medically necessary, individualized compounded medications. Witnesses cited potential practical consequences: steep testing costs per lot, delayed release of sterile parenteral nutrition and pediatric formulations, and the possibility of compounding “deserts” if providers close or stop offering these services.
Stakeholders asked for narrower, risk‑based language. Several pharmacists and supply‑chain experts supported requirements that API suppliers provide valid certificates of analysis and documented provenance, and suggested shifting the burden of supplier verification to regulated suppliers rather than small community pharmacies.
Committee members noted ongoing stakeholder negotiations and that narrower amendments were being discussed; the hearing concluded with an acknowledgement that more work on bill language and exemptions would likely occur before executive action.
The committee closed public testimony and moved HB 2,613 to executive session later in the meeting.
